Celaid Therapeutics Joins Forces with AGC for Research Agreement
Celaid Therapeutics Inc. (Celaid) is thrilled to announce a collaborative research agreement with AGC Inc. (AGC). This partnership aims to enhance the development of induced pluripotent stem cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs), a significant step toward innovative therapies.
Innovative Approaches to iPSC-HSPCs
The collaboration is designed to combine Celaid's advanced hematopoietic stem cell (HSC) expansion technologies with AGC's expertise in iPSC technology. This integration is pivotal in advancing a reliable and scalable method for expanding iPSC-HSPCs, a vital component in the field of regenerative medicine.
Utilizing Celaid’s human HSC expansion expertise, AGC's iPSC-HSPCs will undergo a series of rigorous evaluations. These will include in vitro experiments and in vivo transplantation studies. The focused aim is to demonstrate a reliable method for the large-scale, high-quality production of iPSC-HSPCs, addressing the complex manufacturing hurdles facing the development of therapies derived from these cells.
Leadership Perspectives on the Collaboration
“We are excited to partner with AGC to leverage and combine cutting-edge stem cell technologies to drive future breakthroughs,” commented Nobuyuki Arakawa, the President and CEO of Celaid. His enthusiasm emphasizes the importance of this collaboration as it aligns with resolving the critical challenges prevalent in the clinical manufacturing sector for HSC-derived immune and hematopoietic therapy products.
About Celaid Therapeutics Inc.
Celaid Therapeutics Inc. emerged from the prestigious University of Tokyo and the University of Tsukuba. With unique technology for selective ex vivo HSC expansion, Celaid aspires to deliver next-generation cell and gene therapy solutions. The company focuses on treating hematologic diseases, offering gene therapy for genetic disorders, and enhancing angiogenesis in ischemic diseases.
About AGC Inc.
AGC Inc. is the parent organization of the AGC Group, recognized globally as a premier provider of glass solutions and various high-tech materials. Capitalizing on over a century of technological advancement, the AGC Group offers a vast array of innovative products. They employ roughly 56,000 professionals around the world and report impressive annual sales reaching approximately 2.0 trillion Japanese yen across 30 different countries.
Company Contact Information
Celaid Therapeutics Inc.
Address: UTokyo Entrepreneur Lab, South Clinical Research Building, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8485, Japan
TEL: +81-50-3612-7767
URL: https://celaidtx.com/en/
Frequently Asked Questions
What is the main goal of Celaid's collaboration with AGC?
The primary aim is to enhance the expansion and functionality of iPSC-derived hematopoietic stem and progenitor cells.
What technologies are being combined in this partnership?
The partnership combines Celaid's hematopoietic stem cell expansion technology with AGC's induced pluripotent stem cell technology.
Why are iPSC-HSPCs important in medicine?
iPSC-HSPCs have the potential to revolutionize therapies for blood disorders and immunity by producing quality cell types for treatments.
How will the effectiveness of the expanded cells be evaluated?
The expanded cells will undergo evaluation through in vitro experiments and in vivo transplantation assessments.
What is Celaid Therapeutics working towards?
Celaid is focused on providing innovative cell and gene therapy products aimed at treating hematologic diseases and enhancing regenerative strategies.
